Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allergan, Esprit, Orthovita deal

AGN completed the previously announced acquisition of Esprit for $370 million in cash

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE